KRAS G12C inhibition and innate immune targeting.

ABSTRACT:

Introduction

KRAS mutations drive tumorigenesis by altering cell signaling and the tumor immune microenvironment. Recent studies have shown promise for KRAS-G12C covalent inhibitors, which are advancing rapidly through clinical trials. The sequencing and combination of these agents with other therapies including immune checkpoint blockade (ICB) will benefit from strategies that also address the immune microenvironment to improve durability of response.

Areas covered

This paper reviews KRAS signaling and discusses downstream effects on cytokine production and the tumor immune microenvironment. RAS targeted therapy is introduced and perspectives on therapeutic targeting of KRAS-G12C and its immunosuppressive tumor microenvironment are offered.

Expert opinion

The

SUBMITTER: Tani T 

PROVIDER: S-EPMC8122058 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature